Reconstructiv
Reconstructiv, founded in the early 2020s, is a medical technology company specializing in innovative soft-tissue reconstruction solutions.
Profile
Develops minimally invasive soft-tissue reconstruction solutions.
Reconstructiv, founded in the early 2020s, is a medical technology company specializing in innovative soft-tissue reconstruction solutions. The company has gained traction in the U.S. and European markets, with a focus on providing minimally invasive options that reduce anesthesia use and recovery time. Reconstructiv's flagship product, Preservé, has been well-received globally, contributing to its revenue growth.
In 2025, the company reported $211.1 million in revenue, a 27.2% increase over 2024, and projected 2026 revenue to be between $264 million and $266 million, indicating a 25% growth rate. The company's financials show a significant reduction in net loss from operations, down to $3.9 million in Q4 2025 from $18.7 million in the same period the previous year. Reconstructiv's cash balance stood at $75.6 million at the end of 2025, reflecting a $4.9 million increase from Q3 2025.
The company is poised for its first quarter of positive cash flow in 2026 and anticipates full-year positive cash flow in 2027. Reconstructiv's operational model is now displaying significant leverage, positioning it for sustained growth.
Who buys this
- Plastic surgeons specializing in breast reconstruction
- Patients seeking minimally invasive surgical options
- Hospitals and surgical centers
- Medical device distributors
Strengths and what to watch
Strengths
- Strong revenue growth, with a 27.2% increase in 2025
- Significant reduction in net loss from operations
- Positive adjusted EBITDA in Q4 2025
Watch for
- Dependence on the success of Preservé in key markets
- Regulatory compliance costs impacting R&D expenses
- Potential market saturation in the U.S. and Europe
Key Information
- Founded
- 2020
Frequently Asked Questions
What does Reconstructiv do?
Reconstructiv develops minimally invasive soft-tissue reconstruction solutions, primarily for breast reconstruction. Their technology reduces anesthesia use and recovery time. The company's flagship product, Preservé, has driven significant revenue growth, reaching $211.1 million in 2025 with 27.2% year-over-year increase.
How successful is Reconstructiv's Preservé product?
Preservé has been well-received globally, contributing to Reconstructiv's revenue growth. The product's success helped reduce net losses from $18.7 million to $3.9 million year-over-year in Q4 2025. The company projects continued growth, anticipating positive cash flow in 2026.
Who uses Reconstructiv's medical devices?
Reconstructiv serves plastic surgeons specializing in breast reconstruction, patients seeking less invasive options, hospitals, and medical distributors. Their solutions appeal to those prioritizing reduced recovery time. The company has gained traction in both U.S. and European markets since its early 2020s founding.
Is Reconstructiv financially stable?
Reconstructiv shows strong financial progress, with 2025 revenue reaching $211.1 million (27.2% growth) and cash balances increasing to $75.6 million. Net losses dropped significantly, and the company expects positive cash flow in 2026, projecting 25% revenue growth to $264-266 million.
What are the risks for Reconstructiv?
Key risks include dependence on Preservé's market performance, regulatory compliance costs affecting R&D, and potential saturation in core U.S. and European markets. However, operational leverage has improved, with positive adjusted EBITDA reported in Q4 2025.
How does Reconstructiv compare to traditional reconstruction methods?
Reconstructiv's minimally invasive approach reduces anesthesia requirements and recovery time compared to traditional methods. Their Preservé product offers surgeons and patients an alternative with demonstrated clinical and financial success, though market adoption rates may vary by region.
Sources
- www.sec.gov — Reconstructiv's financial results and 2026 guidance
- www.sec.gov — Financial performance of medical technology companies in 2026
- www.prnewswire.com — Strategic priorities and financial outlook for 2026
- www.sec.gov — Financial reporting standards and metrics